In Vivo Reduction of Reperfusion Injury to the Heart with Apelin-12 Peptide in Rats

• Published in: Bulletin of experimental biology and medicine 2011-11, Vol.152 (1), p.79-82
• Main Authors: Pisarenko, O. I., Serebryakova, L. I., Pelogeykina, Yu. A., Studneva, I. M., Khatri, D. N., Tskitishvili, O. V., Bespalova, Zh. D., Az’muko, A. A., Sidorova, M. V., Pal’keeva, M. E.
• Format: Article
• Language: English
• Subjects: Animals; Biomedical and Life Sciences; Biomedicine; Blood Pressure - drug effects; Cardiotonic Agents - chemical synthesis; Cardiotonic Agents - pharmacology; Cardiotonic Agents - therapeutic use; Cell Biology; Creatine kinase; Creatine Kinase, MB Form - blood; Heart attack; Heart Ventricles - pathology; Intercellular Signaling Peptides and Proteins - chemical synthesis; Intercellular Signaling Peptides and Proteins - pharmacology; Intercellular Signaling Peptides and Proteins - therapeutic use; Internal Medicine; L-Lactate Dehydrogenase - blood; Laboratory Medicine; Male; Myocardial Reperfusion Injury - blood; Myocardial Reperfusion Injury - prevention & control; Nitrates - blood; Nitrites - blood; Nuclear magnetic resonance spectroscopy; Pathology; Peptides; Rats; Rats, Wistar
• ISSN: 0007-4888; 1573-8221
• DOI: 10.1007/s10517-011-1459-9

Apelin-12 (A-12) peptide was synthesized by automated solid phase method and purified by reverse phase HPLC. Its homogeneity and structure were confirmed by HPLC, 1 H-NMR spectroscopy, and mass spectroscopy. Acute myocardial infarction was induced by 40-min occlusion of the left coronary artery with subsequent 60-min reperfusion in narcotized Wistar rats. Peptide A-12 was injected (intravenous bolus, 0.07 or 0.35 μmol/kg) to experimental animals simultaneously with the beginning of reperfusion. Injections of A-12 in these doses led to reduction of systolic BP to 67 and 85% of the initial level, respectively, which was virtually restored completely by the end of reperfusion, and to a significant reduction of the infarction focus in the myocardium (by 21 and 34% in comparison with the control, respectively). Injection of A-12 in a dose of 0.35 μmol/kg led to reduction of plasma concentrations of necrosis markers in comparison with the control by the end of reperfusion: MB-creatine kinase by 56%, lactate dehydrogenase by 30%. The results attest to vasodilatory effects of A-12 under conditions of heart reperfusion in vivo ; the peptide injected after local ischemia limits the myocardial infarction size and reduces damage to cardiomyocyte membrane.